What's The Future of Cancer Immunotherapy? World Renowned Cancer Expert Shares His Perspective

curncman
Posts: 1348
Joined: Fri Jun 26, 2020 8:27 am

Parallel CAR T-Cell Immunotherapy of Solid Tumours by John Maher

Post by curncman »

Parallel CAR T-Cell Immunotherapy of Solid Tumours by John Maher


curncman
Posts: 1348
Joined: Fri Jun 26, 2020 8:27 am

World CRISPR Day 2021 - Session 1 - Cell & Gene Therapy

Post by curncman »

World CRISPR Day 2021 - Session 1 - Cell & Gene Therapy


curncman
Posts: 1348
Joined: Fri Jun 26, 2020 8:27 am

CAR-Ts, NKs, Gene editing: Past, Present and Future of Cell Therapies for Immuno-Oncology

Post by curncman »

CAR-Ts, NKs, Gene editing: Past, Present and Future of Cell Therapies for Immuno-Oncology
Justin Eyquem is quite a unique witness of the emergence of CAR-T cell therapies. He did his PhD in partnership with CAR-T company Cellectis. In 2014, he joined the lab of Michel Sadelain at the MSKCC, who co-founded Juno Therapeutics and is now involved with leading CAR-T cell companies such as Fate Therapeutics and Atara Biotherapeutics. Justin eventually established his own lab at USCF and co-founded Mnemo Therapeutics with Michel Sadelain in 2018. In this episode, we talk about his experience, lessons learned from the first wave of CAR-T cell therapies, as well as the future of the field (NKs, allogeneic strategies, multiplexed gene editing, combinatorial approaches, and more). A great episode !


curncman
Posts: 1348
Joined: Fri Jun 26, 2020 8:27 am

Nektar Therapeutics 2022 J P Morgan Presentation

Post by curncman »

Nektar Therapeutics 2022 J P Morgan Presentation

curncman
Posts: 1348
Joined: Fri Jun 26, 2020 8:27 am

TC BioPharm to Participate in Advanced Therapies Week January 25-28

Post by curncman »

TC BioPharm to Participate in Advanced Therapies Week January 25-28

Tue, January 18, 2022, 8:30 AM·3 min read
EDINBURGH, Scotland, Jan. 18, 2022 /PRNewswire/ -- TC BioPharm (Holdings) Limited ("TC BioPharm"), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications announced today that Executive Chairman and Founder, Dr. Michael Leek will be participating in Advanced Therapies Week in Miami, Florida January 25-28.

Michael will participate in a session titled, Treating Cancer and Covid – Use of Banked Allogeneic Gamma-Delta T Cells in Oncology and Severe Vital Infection. The presentation will take place on Friday January 28th at 9:50 am ET at the Miami Beach Convention Centre. For more information or to register for the event, please visit; https://advancedtherapiesweek.phacilitate.com/

Dr. Michael Leek has 30 years' experience in regenerative medicine, during which he progressed 10 different cell-based products from the laboratory into clinic. In 2017, Michael received the 'Scottish Life-Sciences Entrepreneurial Business Leadership' award for 2016-2017. Michael is also a Fellow of the Royal Society of Medicine and Honorary Lecturer at the University of Aberdeen, School of Medical Sciences.

Advanced Therapies Week is a large and immersive expo for companies in the cell and gene therapy sector. It has a focus on knowledge sharing, relationship building and deal making to advance a major pillar of medicine.
curncman
Posts: 1348
Joined: Fri Jun 26, 2020 8:27 am

The future of BCMA cell therapy is allogenic

Post by curncman »

The future of BCMA cell therapy is allogenic

https://www.fiercebiotech.com/biotech/t ... back-shelf

Autologous chimeric antigen receptor (CAR) T cells, i.e., ones derived from the patient, have no doubt helped changed the face of how we treat certain blood cancers, but a new wind is blowing and caused Poseida a casualty in its pipeline.

The biotech, just last month tapped by Takeda in a major $3.6 billion (largely backloaded biobucks) pact, said it is ditching work on its autologous P-BCMA-101 program in order to focus on its allogenic therapy, known as P-BCMA-ALLO, currently in phase 1 for multiple myeloma.

So-called “off-the-shelf” therapies—allogeneic CAR T cells from donors—often trump autologous approaches, because you can freeze samples and have them on demand, reducing time and costs. This shift has been happening across the industry, and it's now catching up with Poseida.

But there are considerable safety risks in this approach, namely life-threatening graft-versus-host disease, and they may also be rapidly eliminated by the host immune system. Reducing this risk will become the next big priority.

But the risk appears worth taking. In its third-quarter financials reported Tuesday evening, the San Diego biotech said: “The IND clearance [in August] and the start-up of the phase 1 clinical trial mark the beginning of the Company's strategic shift toward focusing on P-BCMA-ALLO1 rather than the autologous P-BCMA-101 program.
Image
“While data in the autologous trial showed meaningful responses and a favorable safety profile, the company's strategic focus has long been on allogeneic CAR-T therapies, leveraging the learnings of the autologous CAR-T program to provide benefits beyond those of autologous CAR-T, including a more desirable off-the-shelf product profile for future commercialization while maintaining the tolerability advantage of our autologous product candidate.”

It added that P-BCMA-ALLO1 has the potential to deliver up to hundreds of doses per manufacturing run, “thereby dramatically reducing both clinical trial costs and ultimately commercial product cost compared to the autologous P-BCMA-101 program.”
Post Reply